移植希望:管理复发性/耐药性AML
Christopher Ronald Funk1, Edmund K Waller1
1Department of Hematology & Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA.
患有高白血病负担的急性髓性白血病 (AML) 患者在干细胞移植后面临着糟糕的结果. 新型移植工程和桥梁疗法显示出改善缓解和生存率的希望.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 急性髓性白血病 (AML) 是一种复杂的血液癌症,复发率高,特别是在诱导治疗后.
- 全基性造血细胞移植 (allo-HCT) 提供了移植对抗白血病 (GVL) 的效果,但在高白血病负担的患者中成功程度有限.
- 移植时的白血病负担和最小残留疾病 (MRD) 阳性是糟糕的生存结果的关键预测因素.
研究的目的:
- 审查新兴策略,以改善患有持续性或复发性AML的患者接受allo-HCT的治疗结果.
- 突出侵略性桥梁疗法和创新的移植工程在管理高白血病负担中的作用.
主要方法:
- 审查当前文献和AML治疗的新兴策略的诱导后疗法.
- 专注于桥梁疗法,包括化疗,低甲基化剂,向抑制剂和顺序诱导-调节 (例如,FLAMSA).
- 评估新的移植工程技术,如ORCA-T,以优化干细胞移植中的T细胞比例.
主要成果:
- 高白血病负担和MRD阳性显著降低了合HCT后的生存率.
- 正在研究积极的桥梁疗法和量身定制的调节方案,以减少移植前的疾病负担.
- 移植工程策略,如ORCA-T,旨在增强GVL效应,同时减轻移植对宿主疾病.
结论:
- 迫切需要改进策略,以克服接受alo-HCT的AML患者的高复发率.
- 创新的方法,包括积极的移植前疗法和先进的移植工程,对改善患者的治疗结果具有重大前景.
- 进一步的临床评估,包括对ORCA-T等方法的III期试验,对于确定它们在治疗复发性/持续性AML中的有效性至关重要.
更多相关视频
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
14:51Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
相关概念视频
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Targeted Cancer Therapies
There are several types of targeted therapies against...
